Core Scientific, Inc./tx
For the period ended Jun 30, 2026. Filed Jul 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
5 — Balance Sheet Components
- BALANCE SHEET COMPONENTS
Customer funding receivable and other current assets consisted of the following at the dates indicated (in thousands):
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Customer funding receivable | $383,758 | $337,158 |
| Other | 74,731 | 25,001 |
| Total customer funding receivable and other current assets | $458,489 | $362,159 |
Customer funding receivable represents amounts due from the Company’s customer for construction-related payables and accrued expenses incurred on their behalf. The Company collects these amounts from the customer prior to payment to vendors. Obligations related to customer items are paid soon after reimbursement. As of June 30, 2026, $302.2 million of the related obligations were included in accrued expenses and $81.6 million were included in accounts payable, compared to $290.6 million in accrued expenses and $46.6 million in accounts payable as of December 31, 2025.
The customer funding receivable is presented net of an allowance for credit losses. The Company evaluates the collectibility of the customer funding receivable under the current expected credit loss model in accordance with ASC 326 and has determined that no allowance for credit losses was required as of June 30, 2026 or December 31, 2025.
Accrued expenses consisted of the following at the dates indicated (in thousands):
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| Accrued customer funded construction | $302,183 | $290,603 |
| Accrued capital expenditures | 105,658 | 197,888 |
| Other | 101,348 | 23,466 |
| Total accrued expenses | $509,189 | $511,957 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.